BRAF and neoplasm: Moreover, the demonstration that co-targeting BRAF/MEK and PI3K enhances the anti-tumor efficacy of PD1 blockade in melanoma indicates that BRAF and PI3K co-inhibition acts not only through direct induction of tumor cell death, but also indirectly by enhancing anti-tumor immunity (Figure 2) [37].